Today, LEO Pharma announced the U.S. Food and Drug Administration’s (FDA) approval for the first and only treatment to target IL-13 cytokine in adults diagnosed with moderate to severe atopic dermatitis. Atopic dermatitis (eczema) is a chronic, inflammatory, skin disease characterized by intense itching, rashes, and lesions. Currently, 16.5 million adults live with the disease in the U.S. and 6.6 million adults have moderate-to-severe cases. The new and approved treatment, adbry (tralokinumab-Idrm) is an injected, antibody drug that works by binding to and inhibiting the IL-13 cytokine, a key protein associated as a driving factor of eczema signs and symptoms. Adbry has been approved for adults 18 and older whose disease cannot be properly managed through additional topical prescription drugs. To date, no cure for the eczema has been developed or approved. LEO Pharma, a Danish pharmaceutical company, uses advanced science and life-changing medicines to develop treatments for moderate to severe dermatological conditions.
Read more here.